SGLT2抑制剂对2型糖尿病患者心肌梗死和卒中的影响
该荟萃分析纳入4项心血管结局试验共42568例受试者,评估SGLT2抑制剂对致死和非致死性心肌梗死及卒中的影响。结果显示SGLT2抑制剂未显著降低心肌梗死或卒中的发生率,但降低了主要不良心血管事件(MACE)。
要点
- SGLT2抑制剂未显著降低致死和非致死性心肌梗死风险,MH风险比0.93(95%CI 0.85-1.01)。
- SGLT2抑制剂未显著降低致死和非致死性卒中风险,MH风险比1.00(95%CI 0.89-1.11)。
- SGLT2抑制剂降低MACE的机制可能不依赖于抗动脉粥样硬化作用。
核心结论
- SGLT2抑制剂降低MACE,但未显著降低心肌梗死或卒中的发生率,可能涉及非抗动脉粥样硬化机制。
研究设计与样本
- 荟萃分析仅纳入事件驱动、随机、安慰剂对照的心血管结局试验,共4项试验,42568例受试者。
主要发现
- 总MACE、心肌梗死和卒中分别报告于4176、2157和1288例受试者。
- 致死和非致死性心肌梗死的MH风险比为0.93(95%CI 0.85-1.01)。
- 致死和非致死性卒中的MH风险比为1.00(95%CI 0.89-1.11)。
- 总动脉粥样硬化性心血管疾病(ASCVD)事件的MH风险比为0.95(95%CI 0.89-1.02)。
- 所有非致死性ASCVD(非致死性心肌梗死和非致死性卒中合并)的MH风险比为0.94(95%CI 0.88-1.02)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have recently been recommended as preferred agents for management of hyperglycemia in type 2 diabetes, primarily based on their ability to reduce a composite of major cardiovascular adverse events (3-point major adverse cardiovascular events [MACE]), predominantly by reducing cardiovascular death. However, reduction of the individual components, myocardial infarction (MI), or stroke (fatal and nonfatal) events have not been well explored. METHODS: In this meta-analysis, we included data available from cardiovascular outcome trials only, which were event-driven, randomized, and placebo-controlled. Pooled efficacy outcomes included Mantel Haenszel (MH) risk ratio using fixed model (with 95% CI) for fatal and nonfatal MI, stroke, and total MI and stroke. FINDINGS: Data from 4 eligible trials included 42,568 subjects. Total MACE, MI, and stroke were reported in 4176, 2157, and 1288 subjects, respectively. SGLT2is did not significantly reduce either MI or stroke individually or in totality. The MH risk ratio (95% CI) for fatal and nonfatal MI and stroke with different SGLT2is was found to be 0.93 (95% CI, 0.85-1.01) and 1.00 (95% CI, 0.89-1.11), respectively. For total atherosclerotic cardiovascular disease (ASCVD) events, MH risk ratio (95% CI) was 0.95 (95% CI, 0.89-1.02). For all nonfatal ASCVD (combined nonfatal MI and nonfatal stroke), MH risk ratio (95% CI) was 0.94 (95% CI, 0.88-1.02). INTERPRETATION: SGLT2is reduce MACE without any discernable significant reduction of the incidence of MI or stroke (fatal and nonfatal), probably implicating mechanisms unrelated to anti-atherogenic effects.
引用
- Mukhopadhyay P, Sanyal D, Chatterjee P, et al. SGLT2 Inhibitors: Effect on Myocardial Infarction and Stroke in Type 2 Diabetes. J Clin Endocrinol Metab. 2023. PMID: 36856812. doi:10.1210/clinem/dgad113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。